Features

How is product innovation faring in the bio/pharma industry thus far in 2024? Through the end of October, FDA’s Center for Drug Evaluation and Research has approved 38 new drugs. Which companies  and products have made the cut, and which may be best poised for market success?

Continual monitoring and evaluation of risk once working with suppliers is critical. An upcoming DCAT webinar will provide a customer–supplier view of the key performance indicators. key risk indicators, challenges, and scenarios to take into consideration to mitigate risk.

The success of mRNA-based COVID-19 vaccines has generated interest in RNA-based drug development, with over 200 RNA drugs estimated to be in development. The promise of RNA medicines in turn has engendered innovation in manufacturing these drugs, including from start-up companies.

With the rate of inflation continuing to moderate, some economists are projecting a soft landing is in place and that overall economic growth is expected to be steady, but some headwinds still remain. What can be expected for the remainder of this year and in the near term?

Novo Holdings’ pending $16.5-billion acquisition of Catalent to acquire sterile manufacturing capacity to support its Type 2 and obesity drugs is a major move in the CDMO drug-product space, What are other key developments.

Biologics, including cell & gene therapies, has been an active area of investment for pure-play biologics CDMOs, but it also has been a target for several CDMOs/CMOs of small-molecule APIs to position themselves or increase their offerings in the biologics space. A roundup of recent developments.

With less than a month before the Presidential and Congressional elections in the US, drug pricing is again front and center on the country’s policy agenda. As different approaches to reduce prescription drug prices emerge, what would be the impact on drug manufacturers?

The shutdown of ports on the US Gulf and East Coasts this week due to a labor strike had the potential for a major impact on the flow of US chemical shipments. With a strike now temporarily diverted, how would have chemical and pharma ingredient supply chains been affected?

Specialty small-molecule drugs are growing more than twice as fast as those of traditional small-molecule drugs. What are some key drugs contributing to this growth, and how is product innovation faring?

As bio/pharma companies and their suppliers seek ways to improve their carbon footprint and meet sustainability targets, what have been recent noteworthy advances in green chemistry in small-molecule drug synthesis?